Vernal keratoconjunctivitis

VerkaziaTM (cyclosporine 0.1%) for the Treatment of Severe Vernal Keratoconjunctivitis is Now Reimbursed by Non-Insured Health Benefits (NIHB) Program

Retrieved on: 
Tuesday, August 17, 2021
Health, Optical, Population, Teva Canada Ltd v Pfizer Canada Inc, Quality of life, Tearing, Ciclosporin, Research, Corneal ulcer, Inflammation, OTC, Vernal keratoconjunctivitis, Patient, Health Canada, Eye, Recurrence, Itch, VKC, Health insurance

Santen is continuing to have discussions with other provinces, territories, and federal agencies regarding the listing of Verkazia under publicly funded drug programs.

Key Points: 
  • Santen is continuing to have discussions with other provinces, territories, and federal agencies regarding the listing of Verkazia under publicly funded drug programs.
  • VKC is a rare and recurrent allergic eye condition, most common in children and adolescents, that causes severe inflammation of the surface of the eye.
  • The treatment should be discontinued if no improvement in signs and symptoms of vernal keratoconjunctivitis is observed.
  • The treatment can be maintained at the recommended dose or decreased to one drop twice daily once adequate control of signs and symptoms is achieved.

Verkazia™ (cyclosporine 0.1%) for the Treatment of Severe Vernal Keratoconjunctivitis is now Publicly Reimbursed in New Brunswick

Retrieved on: 
Wednesday, June 30, 2021
Biotechnology, Pharmaceutical, Optical, Health, Medical specialties, Clinical medicine, Medicine, Vernal keratoconjunctivitis, Keratoconjunctivitis, Conjunctivitis, Autoimmune diseases, Supratarsal injection

Santen is continuing to have discussions with other provinces, territories, and federal agencies regarding the listing of Verkazia under publicly funded drug programs.

Key Points: 
  • Santen is continuing to have discussions with other provinces, territories, and federal agencies regarding the listing of Verkazia under publicly funded drug programs.
  • VKC is a rare and recurrent allergic eye condition, most common in children and adolescents, that causes severe inflammation of the surface of the eye.
  • The treatment should be discontinued if no improvement in signs and symptoms of vernal keratoconjunctivitis is observed.
  • Treatment should be discontinued after signs and symptoms are resolved and reinitiated upon their recurrence.

Santen Receives FDA Approval for Verkazia™ (Cyclosporine Ophthalmic Emulsion) 0.1% for the Treatment of Vernal Keratoconjunctivitis in Children and Adults

Retrieved on: 
Thursday, June 24, 2021
FDA, Health, Clinical trials, Pharmaceutical, Optical, Biotechnology, Medical specialties, Ophthalmology, Clinical medicine, Vernal keratoconjunctivitis, Keratoconjunctivitis, Ciclosporin, Sjögren syndrome

Worldwide, Verkazia is available for the treatment of VKC in select countries across Asia, Europe, and North America.

Key Points: 
  • Worldwide, Verkazia is available for the treatment of VKC in select countries across Asia, Europe, and North America.
  • Verkazia (cyclosporine ophthalmic emulsion) 0.1% is indicated for the treatment of vernal keratoconjunctivitis (VKC) in children and adults.
  • Santen is the market leader for prescription ophthalmic pharmaceuticals in Japan and its products now reach patients in more than 60 countries.
  • Development and testing of quality of life in children with vernal keratoconjunctivitis questionnaire.

Global Vernal Keratoconjunctivitis (VKC) Industry Insights 2017-2030: Epidemiology, Pipeline, Drugs, Reimbursement Scenario, Unmet Needs, Competitive Intelligence

Retrieved on: 
Tuesday, September 1, 2020
Vernal keratoconjunctivitis, Clinical medicine, Medical specialties, Keratoconjunctivitis, Medicine

DUBLIN, Sept. 1, 2020 /PRNewswire/ -- The "Vernal Keratoconjunctivitis (VKC) - Market Insights, Epidemiology, and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Sept. 1, 2020 /PRNewswire/ -- The "Vernal Keratoconjunctivitis (VKC) - Market Insights, Epidemiology, and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The increasing population and rising prevalence of VKC generates a large patient population in the global market.
  • A detailed review of the VKC market; historical and forecasted is included in the report, covering the global drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global VKC market.

Global Vernal Keratoconjunctivitis (VKC) Market Insights, Epidemiology and Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 27, 2020
Managed care, Pharmaceutical, Health, Vernal keratoconjunctivitis, Medical specialties, Clinical medicine, Keratoconjunctivitis, Market, Medicine

The "Vernal Keratoconjunctivitis (VKC) - Market Insights, Epidemiology, and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Vernal Keratoconjunctivitis (VKC) - Market Insights, Epidemiology, and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted global VKC market size from 2017 to 2030.
  • A detailed review of the VKC market; historical and forecasted is included in the report, covering the global drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global VKC market.

Vernal keratoconjunctivitis market size is expected to grow in the forecasted period 2020-2030

Retrieved on: 
Wednesday, August 26, 2020
Keratoconjunctivitis, Medical specialties, Clinical medicine, Vernal keratoconjunctivitis, Medicine, Epidemiology

LAS VEGAS, Aug. 26, 2020 /PRNewswire/ -- DelveInsight has launched a new report ' Vernal keratoconjunctivitis - Market Insights, Epidemiology, and Market Forecast-2030 ' in its repository.

Key Points: 
  • LAS VEGAS, Aug. 26, 2020 /PRNewswire/ -- DelveInsight has launched a new report ' Vernal keratoconjunctivitis - Market Insights, Epidemiology, and Market Forecast-2030 ' in its repository.
  • The Vernal keratoconjunctivitis (VKC) market size in the geographies including 7MM, Saudi Arabia and Egypt, Russia and China is expected to increase during the study period.
  • As per the historical analysis, China accounted for the highest Vernal keratoconjunctivitis market size among all the geographies for the study period 2017-30, followed by Japan and Russia.
  • The Vernal keratoconjunctivitis market report proffers in depth epidemiological segmentation analysis for the study period 2017-30, the epidemiology for this disease is segmented as following in the report:

Vernal keratoconjunctivitis market size is expected to grow in the forecasted period 2020-2030

Retrieved on: 
Wednesday, August 26, 2020
Keratoconjunctivitis, Medical specialties, Clinical medicine, Vernal keratoconjunctivitis, Medicine, Epidemiology

LAS VEGAS, Aug. 26, 2020 /PRNewswire/ -- DelveInsight has launched a new report ' Vernal keratoconjunctivitis - Market Insights, Epidemiology, and Market Forecast-2030 ' in its repository.

Key Points: 
  • LAS VEGAS, Aug. 26, 2020 /PRNewswire/ -- DelveInsight has launched a new report ' Vernal keratoconjunctivitis - Market Insights, Epidemiology, and Market Forecast-2030 ' in its repository.
  • The Vernal keratoconjunctivitis (VKC) market size in the geographies including 7MM, Saudi Arabia and Egypt, Russia and China is expected to increase during the study period.
  • As per the historical analysis, China accounted for the highest Vernal keratoconjunctivitis market size among all the geographies for the study period 2017-30, followed by Japan and Russia.
  • The Vernal keratoconjunctivitis market report proffers in depth epidemiological segmentation analysis for the study period 2017-30, the epidemiology for this disease is segmented as following in the report:

Global Vernal Keratoconjunctivitis Epidemiology 2017-2030

Retrieved on: 
Wednesday, July 15, 2020
Medicine, Medical specialties, Health, Vernal keratoconjunctivitis, Keratoconjunctivitis, Prevalence, Epidemiology

DUBLIN, July 15, 2020 /PRNewswire/ -- The "Vernal Keratoconjunctivitis (VKC) Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, July 15, 2020 /PRNewswire/ -- The "Vernal Keratoconjunctivitis (VKC) Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Population of VKC, Diagnosed Prevalent Population of VKC, Gender-specific Diagnosed Prevalent Population of VKC, Type-specific Diagnosed Prevalent Population of VKC, Severity-specific Diagnosed Prevalent Population of VKC, and Age-specific Diagnosed Prevalent Population of VKC scenario of VKC in the global market from 2017 to 2030.
  • The increasing population and rising prevalence of VKC generates a large patient population in the global market.
  • The report provides the segmentation of the disease epidemiology for the global market by Total Prevalent Population of VKC, Diagnosed Prevalent Population of VKC, Gender-specific Diagnosed Prevalent Population of VKC, Type-specific Diagnosed Prevalent Population of VKC, Severity-specific Diagnosed Prevalent Population of VKC, and Age-specific Diagnosed Prevalent Population of VKC.

Vernal Keratoconjunctivitis (VKC) Epidemiology Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 10, 2020
Health, Other Health, Medicine, Medical specialties, Health, Vernal keratoconjunctivitis, Keratoconjunctivitis, Prevalence, Epidemiology

The "Vernal Keratoconjunctivitis (VKC) Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Vernal Keratoconjunctivitis (VKC) Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Population of VKC, Diagnosed Prevalent Population of VKC, Gender-specific Diagnosed Prevalent Population of VKC, Type-specific Diagnosed Prevalent Population of VKC, Severity-specific Diagnosed Prevalent Population of VKC, and Age-specific Diagnosed Prevalent Population of VKC scenario of VKC in the global market from 2017 to 2030.
  • The increasing population and rising prevalence of VKC generates a large patient population in the global market.
  • The report provides the segmentation of the disease epidemiology for the global market by Total Prevalent Population of VKC, Diagnosed Prevalent Population of VKC, Gender-specific Diagnosed Prevalent Population of VKC, Type-specific Diagnosed Prevalent Population of VKC, Severity-specific Diagnosed Prevalent Population of VKC, and Age-specific Diagnosed Prevalent Population of VKC.

Allakos Announces a Presentation of Antolimab in Patients with Severe Allergic Conjunctivitis at the 2020 ASCRS Virtual Annual Meeting   

Retrieved on: 
Monday, May 11, 2020
Medical specialties, Medicine, Clinical medicine, Immunology, RTT, Immune system, Glycoproteins, Allergic conjunctivitis, Allergology, Vernal keratoconjunctivitis, Keratoconjunctivitis, Conjunctivitis

The virtual presentation will take place on May 16, 2020 at 6:00pm ET.

Key Points: 
  • The virtual presentation will take place on May 16, 2020 at 6:00pm ET.
  • The abstract is currently available on the ASCRS website where the virtual presentation will be available as well.
  • Phase 1b Study of an Anti-Siglec-8 Monoclonal Antibody, Antolimab (AK002), in
    Corneal Disease (VM - 1, Virtual Room 4)
    The Phase 1b clinical trial evaluated antolimab in patients with three forms of severe allergic conjunctivitis refractory to topical treatments; atopic keratoconjunctivitis, vernal keratoconjunctivitis and perennial allergic conjunctivitis.
  • Allakos is a late-stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases.